Rigel Pharmaceuticals | RIGL - Nettoeinkommen

Aktienkurs
31.67
Täglich Wechseln
0.28 0.89%
Monatlich
19.28%
Jährlich
92.06%
Q2 Prognose
28.40




Nettoeinkommen Veränderung Datum
Agenus USD -10.63M 74.49M 2025-12
Amgen USD 1.33B 1.88B 2025-12
Anika Therapeutics USD 292K 2.62M 2025-12
Arrowhead Research USD 30.81M 54.56M 2025-12
AstraZeneca USD 2.33B 207M 2025-12
BioMarin Pharmaceutical USD -46.57M 15.83M 2025-12
Bristol-Myers Squibb USD 1.09B 1.11B 2025-12
Celldex Therapeutics USD -81.32M 14.27M 2025-12
Daiichi Sankyo JPY 86.63B 41.32B 2025-12
Eli Lilly USD 6.64B 1.05B 2025-12
Halozyme Therapeutics USD -141.59M 316.82M 2025-12
Heron Therapeutics USD -2.95M 14.54M 2025-12
Ionis Pharmaceuticals USD -229M 100.39M 2025-12
Karyopharm Therapeutics USD -102.2M 71.42M 2025-12
Ligand Pharmaceuticals USD 117.27M 112.43M 2025-09
MacroGenics USD -14.16M 30.98M 2025-12
Neurocrine Biosciences USD 209.5M 102M 2025-09
Pfizer USD -1.65B 5.19B 2025-12
Regeneron Pharmaceuticals USD 844.6M 615.4M 2025-12
Rigel Pharmaceuticals USD 12.42M 13.45M 2024-09
Sangamo BioSciences USD -36.13M 12.96M 2024-06
Ultragenyx Pharmaceutical USD -129M 51.41M 2025-12
Veracyte USD 41.15M 22.01M 2025-12